Accessibility Menu
Zevra Therapeutics logo

Zevra Therapeutics

(NASDAQ) ZVRA

Current Price$13.11
Market Cap$768.50M
Since IPO (2015)-93%
5 Year-9%
1 Year+44%
1 Month+30%

Zevra Therapeutics Financials at a Glance

Market Cap

$768.50M

Revenue (TTM)

$122.29M

Net Income (TTM)

$124.22M

EPS (TTM)

$2.15

P/E Ratio

6.04

Dividend

$0.00

Beta (Volatility)

0.92 (Low)

Price

$13.11

Volume

414,571.522

Open

$13.00

Previous Close

$13.00

Daily Range

$12.95 - $13.32

52-Week Range

$7.16 - $14.27

Estimated Earnings Date

Aug 11, 2026

ZVRA: Motley Fool Moneyball Superscore

64

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zevra Therapeutics

Industry

Pharmaceuticals

Employees

61

CEO

Neil F. McFarlane

Website

zevra.com

Headquarters

Celebration, FL 34747, US

ZVRA Financials

Key Financial Metrics (TTM)

Gross Margin

85.51%

Operating Margin

-39.86%

Net Income Margin

101.58%

Return on Equity

81.34%

Return on Capital

-1.94%

Return on Assets

44.59%

Earnings Yield

16.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$768.50M

Shares Outstanding

59.12M

Volume

414.57K

Avg. Volume

1.47M

Financials (TTM)

Gross Profit

$104.57M

Operating Income

-$48.75M

EBITDA

$140.47M

Operating Cash Flow

$12.77M

Capital Expenditure

-$771.00K

Free Cash Flow

$12.00M

Cash & ST Invst.

$95.60M

Total Debt

$1.15M

Zevra Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$36.22M

+77.5%

Gross Profit

$33.96M

+78.2%

Gross Margin

93.75%

N/A

Market Cap

$768.50M

N/A

Market Cap/Employee

$13.03M

N/A

Employees

59

N/A

Net Income

$37.89M

+1322.7%

EBITDA

$43.46M

+2455.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$95.60M

+52.6%

Total Debt

$1.15M

-98.1%

Accounts Receivable

$22.10M

+75.1%

Inventory

$2.31M

-9.7%

Long Term Debt

$741.00K

-98.8%

Short Term Debt

$406.00K

-31.1%

Return on Assets

44.59%

N/A

Return on Invested Capital

-21.05%

N/A

Free Cash Flow

$6.11M

+173.4%

Operating Cash Flow

$6.14M

+174.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RIGLRigel Pharmaceuticals, Inc.
$36.75+3.19%
RGNXREGENXBIO Inc.
$10.43+4.82%
OLMAOlema Pharmaceuticals, Inc.
$11.45+8.69%
VTYXVentyx Biosciences, Inc.
$14.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
WENWendy's
$8.00+0.28%
PLSMPulsenmore
$8.83+1.59%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.26+0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.03+0.00%

Questions About ZVRA

What is the current price of Zevra Therapeutics?

Zevra Therapeutics is trading at $13.11 per share.

What is the 52-week range for Zevra Therapeutics?

Over the past 52 weeks, Zevra Therapeutics has traded between $7.16 and $14.27.

How much debt does Zevra Therapeutics have?

As of the most recent reporting period, Zevra Therapeutics reported total debt of $1.15M.

How much cash does Zevra Therapeutics have on hand?

Zevra Therapeutics reported $95.60M in cash and cash equivalents in its most recent financial results.

What is Zevra Therapeutics’s dividend yield?

Zevra Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.